PharmaCyte Biotech, Inc. (PMCB): Business Model Canvas [Dec-2025 Updated]

You're looking at a biotech firm in a real holding pattern, and PharmaCyte Biotech, Inc.'s current business model clearly shows that pivot. Honestly, the main event-their CypCaps™ cell therapy for pancreatic cancer-is sidelined by an FDA clinical hold, so the company has drastically shrunk its operational footprint to just 2 employees while sitting on about $20 million in cash and securities as of late 2025. This means their immediate value proposition isn't a drug, but strategic capital deployment, aiming for investment gains while they tackle the regulatory hurdles; this canvas details exactly how PharmaCyte Biotech, Inc. is managing this unusual transition from pure R&D to a lean investment manager, and you need to see the details to understand the near-term risk profile.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Key Partnerships

You're looking at the core relationships that keep PharmaCyte Biotech, Inc. moving forward, especially as they navigate the complex path toward FDA approval for their lead candidates. These aren't just vendor agreements; these are strategic alliances that provide capital, manufacturing capability, and scientific validation. Honestly, in this sector, your partners are as critical as your pipeline.

The Key Partnerships block of the Business Model Canvas shows a mix of financial backers, technology providers, and service executors. Here's the breakdown of the most material relationships as of late 2025, grounded in the latest public disclosures.

Strategic Financial and Governance Alliances

The relationship with Iroquois Master Fund Ltd. is a prime example of how shareholder activism can reshape governance and strategy. This partnership solidified a new Board structure, which is defintely a key resource for strategic direction.

• Iroquois Master Fund Ltd. and its affiliates signed a Cooperation Agreement with PharmaCyte Biotech, Inc. on August 15, 2022.
• As of that date, Iroquois Master Fund Ltd. and its affiliates were the beneficial owners of approximately 6.7% of PharmaCyte Biotech's outstanding common stock.
• The Cooperation Agreement included a provision for PharmaCyte to reimburse the Iroquois Parties for reasonable, documented out-of-pocket fees and expenses not to exceed $637,570 in aggregate.

PharmaCyte Biotech also actively manages its investment portfolio, which includes a significant stake in TNF Pharmaceuticals (TNFA). This is a financial partnership that has seen recent capital deployment.

Here's a quick look at the financial activity related to this investment as of late 2025:

Partner Entity	Transaction Type	Amount/Date	Context
TNF Pharmaceuticals (TNFA)	Increased Investment	$3,000,000 (September 2025)	To support TNF's licensing agreement for LightSolver's processing accelerator technology.
Existing Investors (Private Placement)	Financing Close	$7,000,000 (August 2025)	Sale of Series C convertible preferred stock and warrants.
PharmaCyte Biotech, Inc.	Total Assets Reported	Over $55,000,000 (As of April 30, 2025)	Indicates capital position supporting strategic activities.

Regarding Q/C Technologies, Inc., while listed as a key partnership involving a strategic investment of $3,000,000 in your outline, the latest available public data confirms a $3 million investment by PharmaCyte Biotech into TNF Pharmaceuticals, but does not explicitly detail a $3,000,000 strategic investment from Q/C Technologies, Inc. to PharmaCyte Biotech in the search results near November 2025.

Operational and Manufacturing Collaborations

The success of the Cell-in-a-Box technology hinges on specialized external expertise for regulatory compliance and production.

Contract Research Organizations (CROs) are essential for meeting the U.S. Food and Drug Administration (FDA) requirements to lift the clinical hold on the Investigational New Drug Application (IND).

• PharmaCyte Biotech engages closely with leading Contract Research Organizations (CROs) for mandated studies.
• The company designed and commenced 8 biocompatibility studies required by the FDA.
• Of those, 6 studies have been reported as completed successfully.
• Agreements with CROs generally allow for termination at any time, which is a near-term operational risk.

Austrianova serves as the critical manufacturer for the proprietary encapsulation system.

For the FDA-required studies, Austrianova provided the necessary materials:

• Austrianova manufactured and delivered an additional 400 syringes of empty Cell-in-a-Box capsules.
• The encapsulation facility operated by Austrianova is required to be cGMP (current Good Manufacturing Practices-compliant).
• PharmaCyte Biotech entered into a Binding Memorandum of Understanding with Austrianova in July 2016.

Finance: draft updated cash flow projection incorporating the August 2025 financing by end of next week.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Key Activities

You're looking at the core things PharmaCyte Biotech, Inc. is actively doing to move the needle, given their lean structure. Here's the breakdown of their Key Activities as of late 2025, grounded only in the numbers we see.

Strategic capital deployment and investment management

PharmaCyte Biotech, Inc. is definitely focused on managing its cash position through strategic moves. They successfully monetized their stake in Femasys Inc., which is a clear deployment action. This move is expected to push their cash position up to approximately $20 million, coming from $13.3 million as of July 31, 2025. Anyway, the most recent 10Q values their total cash and marketable securities at roughly $20 million in cash plus approximately $25 million in marketable securities. To be fair, they also executed a financing in August 2025, bringing in $7.0 million through the sale of 7,000 shares of Series C convertible preferred stock, each with a stated value of $1,000. These shares accrue a 7.0% quarterly dividend. The capital structure also involves warrants exercisable at $1.00 per share for a term of five years.

Here's a quick look at the balance sheet strength as of Fiscal Year 2025:

Financial Metric (in Thousands USD)	FY 2025 Amount
Total Assets	55,168
Total Debt	0
Net Income	30,656
Accumulated Deficit	(93,329,056)

Addressing the FDA clinical hold for CypCaps™ IND

The primary R&D activity centers on fulfilling the U.S. Food and Drug Administration (FDA) requests to lift the clinical hold on the Investigational New Drug Application (IND) for their pancreatic cancer treatment. The team is working through a list of items, some of which were detailed on pages 28 and 29 of the Form 10-Q for the period ending January 31, 2021. This is a major operational focus.

Conducting preclinical studies (e.g., stability, biocompatibility)

To satisfy the FDA, PharmaCyte Biotech, Inc. has designed and commenced several specific preclinical studies. These are definitely key activities supporting the IND resubmission:

• Subchronic and Chronic Toxicity study
• Skin Sensitization study
• Acute Systematic Toxicity study
• Ames test [Genotoxicity Bacteria and Reverse Mutation tests]
• Intracutaneous test
• Complement Activation test
• Hemolysis test
• In Vitro Cytotoxicity test
• In Vivo Micronucleus assay

Also, they completed production and shipping of test materials for biocompatibility studies. Back in July 2022, they had reached the 3-year stability timepoint for cells from their Master Cell Bank (MCB). Furthermore, they commenced a pig study, with a pilot phase involving 2 pigs, designed to finalize the protocol for a full-scale study involving 90 pigs.

Corporate governance and shareholder value initiatives

You can see shareholder engagement through recent votes. At the Annual Meeting on April 24, 2025, 3,222,988 shares of common stock, representing approximately 46.92% of outstanding shares, were represented. Also, in October 2025, stockholders approved increasing the shares available for grants under the 2022 Equity Incentive Plan by 2,250,000 shares. This follows a previously authorized share repurchase program of up to $10 million.

Key share structure data as of July 31, 2025:

• Common Stock Issued: 21,672,095 shares
• Common Stock Outstanding: 6,795,779 shares
• Stock Price (as of Sep 15, 2025): $1.03
• Market Capitalization (as of Sep 15, 2025): $7M

Managing a very small operational footprint (2 employees)

The operational footprint is extremely tight. PharmaCyte Biotech, Inc. had 2 employees as of April 30, 2025. This number did not change compared to the previous year. The Revenue / Employee metric is listed as n/a, but Profits / Employee is listed as $22,227.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Key Resources

You're looking at the core assets PharmaCyte Biotech, Inc. (PMCB) relies on to execute its strategy, especially given its clinical-stage focus. Honestly, for a company this size, the resources are highly concentrated in intellectual property and recent capital maneuvers. Here's the quick math on what they have locked down as of late 2025.

The financial foundation is critical right now. Following a strategic move to monetize a stake in Femasys Inc., the company reported a significant boost to its liquidity. This is the kind of deft financial play that gives a small biotech breathing room to advance its pipeline.

Financial Metric	Value (Late 2025)	Reference Date/Context
Cash and Marketable Securities	$20,000,000	Post-Femasys Monetization
Total Assets	$45,110,453	As of July 31, 2025
Cash and Cash Equivalents (Specific Line Item)	$13,178,305	As of July 30, 2025
Investment in preferred stock - TNF (Partial Asset)	$19,635,000	As of July 31, 2025

The human capital side is lean, which is typical for a company focused on advancing a specific technology platform through clinical stages. You'll see that the team size is minimal, meaning key personnel are definitely wearing multiple hats. What this estimate hides is the reliance on external consultants and scientific advisors to augment this small core team.

The true value driver, however, remains the technology itself. This IP is what underpins the entire business thesis for both their cancer and diabetes programs.

• Proprietary Cell-in-a-Box® live-cell encapsulation technology IP.
• Small, focused executive and scientific team: 2 employees as of late 2025.
• Listing on the Nasdaq stock exchange (NasdaqCM).

The Nasdaq listing is a resource because it provides public market access for capital raising, even if the market capitalization is currently small-around $5.1 million as of late November 2025. Finance: draft 13-week cash view by Friday.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Value Propositions

PharmaCyte Biotech, Inc.'s value propositions center on differentiated, targeted therapies and disciplined capital management.

Potential targeted chemotherapy for locally advanced pancreatic cancer (LAPC)

PharmaCyte Biotech, Inc. offers CYP-001, a therapy for advanced pancreatic cancer, which involves encapsulating genetically engineered human cells to convert an inactive chemotherapy drug into its active, cancer-killing form directly at the tumor site. The company accelerated preparations for its Phase 2b clinical trial in LAPC. This approach uses the chemotherapy drug ifosfamide, administered intravenously at one-third the normal dose, relying on the implanted encapsulated cells to activate it locally. Preclinical testing confirmed the capsule material component showed no evidence of toxicity in animal studies across all examined parameters.

Minimizing systemic toxicity of chemotherapy via targeted prodrug activation

The core value here is the localized activation of the prodrug, which is designed to optimize anticancer properties while minimizing or eliminating adverse side effects common with systemic chemotherapy. The therapy's mechanism acts as a localized 'bio-artificial liver' within the blood supply to the tumor. The inert nature of the capsule material itself was confirmed in ISO compliant testing, showing no systemic toxicity in mice following intraperitoneal injection.

Potential bio-artificial pancreas for Type 1 and Type 2 diabetes

PharmaCyte Biotech, Inc. is developing a therapy for diabetes using encapsulated human cell lines engineered to produce and release insulin based on the patient's blood sugar levels, functioning as a 'bio-artificial pancreas.' This addresses a significant market. The global Diabetes Care Devices market was estimated at $65.74 billion in 2025. Type 2 Diabetes accounted for 88.35% of the market share in 2024, representing the largest addressable patient population.

Here's a quick look at the market context for the diabetes segment:

Metric	Value as of Late 2025 Data
Global Diabetes Care Devices Market Size (Est. 2025)	$65.74 billion
Projected CAGR (2025-2030)	6.94%
Type 2 Diabetes Market Share (2024)	88.35%

Strategic investment returns to maximize shareholder value

PharmaCyte Biotech, Inc. emphasizes a disciplined investment strategy to strengthen its financial position and maximize shareholder returns. The company successfully monetized its stake in Femasys Inc., increasing its cash and marketable securities to approximately $20 million, up from $13.3 million as of July 31, 2025. Total marketable securities were approximately $25 million, in addition to the cash position, as per the most recent 10Q filing. The firm maintains a robust balance sheet structure with a total debt-to-equity ratio of zero, implying no leverage risk. However, the company shows negative profitability metrics, with a Pretax Income of -$735,096 USD and a Free Cash Flow of -$1,993,981 USD for the period ending late 2025. The Return on Assets was -3.94% and Return on Equity was -7.71%. As of December 4, 2025, the Market Cap stood at $8.9 million, reflecting a decrease of -29.35% over one year. The Price to Book ratio was 0.12, while the Quick Ratio was 12.7, indicating strong liquidity.

Key financial structure points as of July 31, 2025, include:

• Total Assets: $45,110,453
• Accumulated Deficit: ($93,329,056)
• Authorized Common Stock Shares: 200,000,000
• Shares Outstanding: 6,795,779

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Customer Relationships

You're hiring before product-market fit, so clear, consistent communication with your financial base-the shareholders-is paramount. PharmaCyte Biotech, Inc. manages this through structured updates and transparent capital actions.

High-touch communication with shareholders via strategic updates

PharmaCyte Biotech, Inc. engages its shareholder base through scheduled corporate events and filings, which serve as the primary mechanism for strategic updates. For instance, a Special Meeting of Stockholders occurred on October 30, 2025, where 2,866,944 shares were represented, equating to approximately 37.1% of the outstanding voting stock entitled to vote.

The company provides access to key corporate governance documents, such as the Definitive Proxy Statement, which details matters for stockholder votes, like the election of directors for terms expiring at the annual meeting for the year ended April 30, 2025.

• Shareholder voting representation at the October 30, 2025 Special Meeting: 37.1%.
• Shares represented at the October 30, 2025 Special Meeting: 2,866,944.
• Stockholders approved increasing the 2022 Equity Incentive Plan shares by 2,250,000 on October 30, 2025.

Regulatory relationship management with the U.S. FDA

The relationship management with the U.S. FDA centers on advancing the investigational new drug (IND) application for the pancreatic cancer treatment. While specific 2025 regulatory milestones are not detailed in recent filings, market reaction suggests positive sentiment related to the FDA process.

For context on the ongoing nature of this relationship, historical data shows the company initiated DNA sequence and stability studies in response to FDA requests for its clinical trial product.

• Stock price movement on December 04, 2025, was up 31.91% following reports of 'FDA approval excitement.'
• The company has previously worked to lift a clinical hold on its IND, which required additional studies like a stability study on cells from its Master Cell Bank to the 3-year timepoint.

Investor relations focused on capital deployment transparency

Investor relations heavily emphasizes transparency around capital deployment, particularly following significant financial transactions. The successful monetization of the Femasys Inc. stake is a key recent example of this strategy in action.

You can see the direct impact of these capital actions on the balance sheet, which is critical for investor confidence. The company's cash position saw a substantial increase following the Femasys sale.

Here's the quick math on the cash position change:

Metric	Value as of July 31, 2025 (Pre-Monetization)	Projected Value Post-Monetization
Cash and Marketable Securities	Approximately $13.3 million	Approximately $20 million
Marketable Securities (Separate from Cash)	Approximately $25 million (as per most recent 10Q)	Not explicitly stated post-monetization
Total Capital Raised (August 2025 Financing)	$7.0 million	N/A
Q/C Investment Closed	$3,000,000 (Closed September 4, 2025)	N/A

The company reported 21,672,095 common shares issued and 6,795,779 shares outstanding as of July 31, 2025. The stock recently traded at $0.65 per share, with approximately 6.8 million shares outstanding, and the price saw a 9.9% increase on December 05, 2025.

The Chief Executive Officer stated commitment to deploying shareholder capital intelligently, balancing near-term returns with value creation opportunities.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Channels

The channels PharmaCyte Biotech, Inc. (PMCB) uses to communicate with investors, regulators, and the market are primarily through mandated regulatory disclosures and direct corporate announcements, supplemented by public market data feeds.

SEC Filings (10-K, 10-Q, 8-K) for financial and strategic updates

PharmaCyte Biotech, Inc. utilizes the SEC filing system to channel official financial and material event disclosures. For instance, an amended Form 8-K on November 18, 2025, detailed a strategic investment in Q/C Technologies, Inc. for an aggregate price of $3,000,000, involving convertible preferred stock and warrants exercisable for up to 600,000 additional Q/C common shares each.

Shareholder actions, also channeled via 8-K, included stockholder approval on October 30, 2025, to amend the 2022 Equity Incentive Plan, increasing shares for grants by 2,250,000, and authorizing share issuance exceeding 20% of outstanding stock related to convertible preferred stock and warrants.

Key balance sheet figures are reported through these filings. As of April 30, 2025, PharmaCyte Biotech, Inc. reported approximately $15.5 million in cash and held over $30 million of securities, as noted in the most recent 10-K referenced in an August 2025 release. The company's latest reported net income for the last quarter was $\text{-}8.36 \text{ M USD}$.

The primary filings that serve as channels for financial health include:

• 10-K Filing: Year End Results for the period ending April 30, 2025.
• 10-Q Filing: Quarterly Results for Q3 2025, released January 31, 2025.
• 8-K Filing: Material Event reported on October 31, 2025.

Corporate Press Releases for clinical and investment news

Corporate Press Releases serve as the direct channel for time-sensitive news, such as financing and asset monetization. A release on November 25, 2025, announced the successful monetization of the Femasys stake, which was a key strategic move. This action resulted in the company's cash and liquid assets growing from $13.3M to a total of $20M.

Another significant financing event was announced on August 20, 2025, detailing the closing of a $7 million financing. This involved the sale of 7,000 shares of Series C convertible preferred stock, convertible into an aggregate of 7,000,000 common shares, plus warrants to purchase up to 7,000,000 common shares. The preferred stock accrues a 7.0% quarterly dividend payable in cash.

Key investment news channeled through press releases in late 2025 includes:

• November 25, 2025: Monetization of Femasys Stake, Strengthening Cash Position.
• September 2, 2025: Increase in Stake in TNF Pharmaceuticals.
• August 20, 2025: Closing of $7 Million Financing.

Nasdaq Stock Exchange for public trading and liquidity

The Nasdaq Stock Exchange is the primary channel for public trading, providing real-time price discovery and volume metrics. As of December 3, 2025, the closing price was $0.7846, reflecting a 5.02% increase on that day, with a trading volume of 669,051 shares. The company is listed on the NASDAQ-CM.

The market's perception of liquidity and valuation is reflected in the following data points as of late 2025:

Metric	Value	Date/Context
Market Capitalization	$8.22 M	Late 2025
Market Capitalization	$6.00 M	Late 2025
52 Week High	$1.90	Last 52 Weeks
52 Week Low	$0.63	Last 52 Weeks
All-Time Low Price	$0.6300 USD	Reached November 19, 2025
Trading Range	$0.61 (Low) to $1.20 (High)	November 25, 2025
Average Daily Volume	5.83 M	Average
Employees	2	As of December 5, 2025

The stock has shown recent price movement, falling $\text{-}9.81%$ compared to the previous week and $\text{-}24.38%$ over the last year. The company does not pay dividends.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Customer Segments

You're mapping out the core groups PharmaCyte Biotech, Inc. (PMCB) needs to serve to make its Cell-in-a-Box® technology a commercial success. This isn't just about the end-user patient; it's about the entire ecosystem that enables the therapy to reach them, starting with the capital that funds the journey.

Biotech Investors and Shareholders seeking capital appreciation

This segment is crucial right now as PharmaCyte Biotech, Inc. (PMCB) is pre-revenue, with reported revenue of $0 million for the fiscal year ended April 30, 2025. Their interest is tied directly to the company's financial health and future potential. As of the latest reports, the company recently closed a $7.0 million financing in August 2025. The market capitalization as of September 15, 2025, was $7M, with the stock trading at $1.03. Ownership structure shows that Institutional Ownership stands at 8.57%, while Insider Ownership is 10.64%. The share count provides context for potential dilution and per-share value; as of July 31, 2025, there were 21,672,095 shares issued, with approximately 6.8 million common shares outstanding as of August 20, 2025. The company reported a net loss of -$8.36M last economic quarter, though net income for the fiscal year ending April 30, 2025, was $30.66 million, largely due to investment gains.

Oncologists and Hepatologists treating LAPC (future)

These are the specialists who will prescribe and manage the CypCaps™ therapy for locally advanced, inoperable pancreatic cancer (LAPC). The target market size for this indication is defined by the incidence of pancreatic cancer. For 2025 in the U.S., an estimated 67,440 new cases are projected. PharmaCyte Biotech, Inc. (PMCB)'s therapy targets the localized stage, which accounted for 15% of cases diagnosed between 2015 and 2021. The sheer number of specialists required to treat this patient base is significant, though a specific count for Hepatologists is not available. We can look at the broader oncology workforce as a proxy for the treating specialists.

Specialist Group	Relevant Count/Statistic	Date/Period of Data	Source Context
Total Actively Practicing Oncologists (U.S.)	25,419	2025	Active practice in the United States
Oncologists Billing Medicare (U.S.)	14,547	2024	Reported number
Hematology/oncology Physicians Tracked	11,937	October 2025	Most common tracked specialty
Medical Oncology Physicians Tracked	4,778	October 2025	Tracked specialty
Projected U.S. Oncologist Shortage	2,250	By 2025	Earlier projection

Patients with locally advanced, inoperable pancreatic cancer (future)

This is the initial, high-unmet-need patient population for the CypCaps™ product candidate. The overall pancreatic cancer incidence in the U.S. for 2025 is estimated at 67,440 new cases. The five-year relative survival rate for localized disease is 43.6%, compared to 3.2% for distant metastatic disease. The company's technology involves implanting encapsulated cells near the tumor site to activate a chemotherapy drug like ifosfamide.

Patients with insulin-dependent Type 1 and Type 2 diabetes (future)

This represents a significant, long-term expansion market for PharmaCyte Biotech, Inc. (PMCB)'s platform technology. The market for diabetes treatments is substantial, with the global Type 2 Diabetes Market size valued at $40.09 billion in 2025, and the U.S. segment at $10.82 billion. For Type 1 Diabetes, the global market was estimated at $16.97 Bn in 2025. The patient base in North America alone is large, with over 29 million people affected by diabetes, projected to rise to 32 million by 2025. Globally, the total number of people living with diabetes was 588.71 million in 2024.

• Global Type 2 Diabetes Market Size (2025): $40.09 billion
• U.S. Type 2 Diabetes Market Size (2025): $10.82 billion
• Global Type 1 Diabetes Market Size (2025 Estimate): $16.97 Bn
• North America Diabetes Prevalence (2025 Projection): 32 million people
• Global Diabetes Prevalence (2024): 588.71 million people

The Diabetes Stem Cell Therapy Market itself was valued at $5.4 Bn in 2024.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Cost Structure

You're looking at the core outflows for PharmaCyte Biotech, Inc. as of late 2025. For a company in clinical development, the cost structure is almost entirely non-revenue generating, focused on compliance, science, and keeping the lights on. It's a lean operation, but the costs associated with regulatory hurdles are significant.

The most immediate, non-recurring cost pressure comes from resolving the FDA clinical hold on the Investigational New Drug Application for pancreatic cancer. PharmaCyte Biotech, Inc. has engaged in specific service agreements to address the FDA's requests. The estimated total cost for these efforts is $212,000, with a portion of that, $157,000, specifically related to services from SG Austria and its subsidiaries to generate the necessary data submissions. This is a direct, targeted cost to unlock future revenue potential.

Research and Development (R&D) expenses, along with General and Administrative (G&A) expenses, form the bulk of the recurring operational spend. Looking at the quarter ended January 31, 2025, the total operating expenses were $960,252. For the nine-month period ending January 31, 2025, these operating expenses totaled $3,335,998. To be fair, these figures reflect a conscious reduction in costs from the prior year, specifically citing decreases in R&D costs, director fees, and general administrative costs.

Here's a quick look at the scale of those operating costs relative to the top-line result for that nine-month period:

Cost Category	Amount (Nine Months Ended Jan 31, 2025)
Total Operating Expenses	$3,335,998
Estimated FDA Hold Related Costs (Partial)	$212,000
Net Loss (Recent Quarter)	Approximately -$8.36 million

Personnel costs are kept to an absolute minimum, which is a key factor in managing the burn rate. As of April 30, 2025, PharmaCyte Biotech, Inc. maintained a very small core team, reporting only 2 employees. This minimal headcount directly contributes to lower compensation expenses, though compensation was still a line item that saw reductions in the nine months ended January 31, 2025.

The ultimate measure of the cost structure's impact on the bottom line is the net loss. For a recent economic quarter, the company reported a significant net loss of approximately -$8.36 million. This loss figure, while substantial, is viewed against a backdrop of strong liquidity following strategic asset monetization, suggesting management is funding the current cost base from reserves rather than immediate operations.

The cost structure is characterized by:

• Regulatory compliance spending directly tied to FDA resolution.
• Curtailment of R&D spending to conserve capital.
• Minimal G&A overhead due to a lean structure.
• Personnel costs anchored by a team of 2 employees.

Finance: draft 13-week cash view by Friday.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of PharmaCyte Biotech, Inc.'s business model as of late 2025. For a company focused on clinical development, the revenue streams are currently dominated by non-operational activities, namely strategic capital deployment and financing events, rather than product sales.

Investment Gains from Strategic Capital Deployment

PharmaCyte Biotech, Inc. executed a significant move in late 2025 by successfully monetizing its stake in Femasys Inc. (NASDAQ: FEMY). This action validated the Company's strategic approach to capital allocation. Following this monetization, PharmaCyte's cash and marketable securities are expected to increase to approximately $20 million, which is up from $13.3 million as of July 31, 2025. This transaction is part of a broader strategy to strengthen the balance sheet.

To give you the full picture of the liquidity position around this event, here's a look at the key figures:

Metric	Date/Period End	Amount	Context
Cash and Securities	April 30, 2025	Approximately $15.5 million in cash and over $30 million in securities
Cash and Securities	July 31, 2025	$13.3 million
Capital Raise Proceeds	August 2025	$7 million
Cash and Securities (Expected Post-Monetization)	November 2025	Approximately $20 million
Total Cash and Marketable Securities (Post-Monetization)	November 2025	Roughly $20 million in cash plus approximately $25 million in marketable securities

The company is committed to deploying shareholder capital intelligently, balancing near-term returns with sustained value creation opportunities.

Recent Capital Raise

PharmaCyte Biotech, Inc. closed a financing round in August 2025, securing $7 million. This was achieved through a private placement involving the sale of Series C convertible preferred stock. The successful completion of this financing strengthened the balance sheet, providing financial flexibility to support ongoing business initiatives.

Key details of the August 2025 raise include:

• The financing involved the sale of 7,000 shares of Series C preferred stock.
• Each preferred share had a stated value of $1,000.
• The preferred stock is convertible into an aggregate of 7,000,000 shares of common stock.
• The conversion price is $1.00 per share of common stock.
• Unregistered common stock purchase warrants were issued to purchase up to 7,000,000 shares of common stock.
• Warrants are exercisable immediately at an exercise price of $1.00 per share for a term of five years.
• As of the release date, PharmaCyte had approximately 6.8 million shares of common stock outstanding.

Future Potential Licensing or Collaboration Revenue

As of late 2025, PharmaCyte Biotech, Inc. reports its future potential licensing or collaboration revenue as $0.

Future Potential Product Sales of CypCaps™

The Company's lead product candidate, CypCaps™, which uses the Cell-in-a-Box® technology for cellular therapies, currently generates no direct product sales revenue. As of late 2025, future potential product sales of CypCaps™ are reported as $0.

It's important to note that PharmaCyte Biotech's total operating revenue for the fiscal year 2025 ending April 30, 2025, was reported as $0.0. For the three months ended January 31, 2025, the total operating revenue was reported as -960,252 yuan, which was an improvement from the prior year's equivalent loss.